The above chart presents the market trend analysis for novartis pharma ag. from 2025 to 2026.
By examining various dimensions such as transaction quantity, transaction weight, average price,
and transaction frequency, we can gain an intuitive understanding of the company's performance in terms of procurement cycles, business scale, and stability.
As of 2026, the company has completed 423 transactions, with a transaction quantity of 1182055.84 and a transaction weight of 17484.34.
Suppliers
novartis pharma ag.
Buyers
novartis de col s.a.
POLs
——
PODs
bogota
Supply area
Switzerland
Purchas area
Colombia
Weight
5.98kg
Amount
19004.75
Hs code
3002121900
Product tags
antisera
Product description
EMPAQUE PRESENTACION DEL PRODUCTO JERINGA PRELLENADA EN ENVASE DE VIDRIO INCOLORO DE 2.25ML CON AGUJA DE 27GX1 2 RECUBIERTA CON UN TAPON DE EMBOLO DE GOMA REVESTIDO Y UN PROTECTOR DE AGUJA RIGIDO. EMPAQUE CAJA DE CARTON ETIQUETADA SELLADA CON UN SELLO DE SEGURIDAD USO ESTUDIO DE FASE 3 ALEATORIZADO DOBLE CIEGO CON GRUPOS PARALELOS CONTROLADO CON PLACEBO MULTICENTRICO PARA EVALUAR LA EFICACIA SEGURIDAD Y TOLERABILIDAD DEL IANALUMAB
Expand
Trade date
2026/05/26
B/L No.
92003008337941
Suppliers
novartis pharma ag.
Buyers
novartis de col s.a.
POLs
——
PODs
bogota
Supply area
Switzerland
Purchas area
Colombia
Weight
0.32kg
Amount
1001
Hs code
3006930000
Product tags
——
Product description
ESPECIALIZADA DE MEDICAMENTOS Y PRODUCTOS BIOLOGICOS CODIGO DEL PROTOCOLO ASIGNADO POR INVIMA PI NO 1599 CODIGO DEL PROTOCOLO CVAY736K12301 NUMERO DEL RADICADO CON EL CUAL SE SOLICITA EL CONCEPTO 20241171868 PRODUCTO NOMBRE DEL MEDICAMENTO COMPARADOR Y O PLACEBO VAY736 PLACEBO SYRINGE NOMBRE COMERCIAL VAY736 PLACEBO SYRINGE PRINCIPIO ACTIVO VAY736 PLACEBO CONCENTRACION 0MG INDICACIONES TERAPEUTICAS ESTUDIO DE FASE 3 ALEATORIZADO DOBLE CIEGO CON GRUPOSPARALELOS CONTROLADO CON PLACEBO MULTICENTRICO PARA EVALUAR LA EFICACIA SEGURIDAD Y TOLERABILIDAD DEL IANALUMAB AGREGADO AL TRATAMIENTO ESTANDAREN PACIENTES CON
Expand
Trade date
2026/05/15
B/L No.
92003008079948
Suppliers
novartis pharma ag.
Buyers
novartis de col s.a.
POLs
——
PODs
bogota
Supply area
Switzerland
Purchas area
Colombia
Weight
7.63kg
Amount
15427.79
Hs code
3004902900
Product tags
equipped with fixed dose drug
Product description
CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE REMIBRUTINIB EN PACIENTES CON ESCLEROSIS MULTIPLE SECUNDARIA PROGRESIVA FORMA FARMACEUTICA COMPRIMIDO RECUBIERTO DE LIBERACION PROLONGADA TIPO DE EMPAQUE PRESENTACION DEL PRODUCTO ENVASE BOTELLAS DE POLIETILENO DE ALTA DENSIDAD CON SELLO DE INDUCCION Y CIERRE A PRUEBA DE NIÑOS. EMPAQUE CAJA DE CARTON ETIQUETADA SELLADA CON UN SELLO DE SEGURIDAD 79 BOTELLAS CADA UNA CON 35 COMPRIMIDO RECUBIERTO DE LIBERACION PROLONGADA PARA UN TOTAL DE 2765 COMPRIMIDO RECUBIERTO DE LIBERACION USO HUMANO MARCA LOU064 NUMERO Y TIPO DE DOCUMENTO RESOLUCION NO. 2025061888 FECHA AÑO DE EMISION DEL DOCUMENTO INVIMA
Expand
Trade date
2026/05/15
B/L No.
92003008079955
Suppliers
novartis pharma ag.
Buyers
novartis de col s.a.
POLs
——
PODs
bogota
Supply area
Switzerland
Purchas area
Colombia
Weight
1.27kg
Amount
2578.13
Hs code
3006930000
Product tags
——
Product description
PARA ESTUDIOS CLINICOS NOS ACOGEMOS A LA RESOLUCION 057 DEL 13 DE ABRIL DE 2015 MERCANCIA NUEVA CUENTA CON VINVIMA 25 0173075 FECHA APROBACION 2025 12 10. FACTURA 1000073500 FECHA 07 05 2026 DP BATCH 1010052321 CFG BATCH A0NRRL PCN 1000000078 1000000080 MATERIAL NO 2161640 PRODUCTO NOMBRE DEL MEDICAMENTO COMPARADOR Y O PLACEBO LOU064 0MG FILM COATED PLACEBO NOMBRE COMERCIAL LOU064 0MG FILM COATED PLACEBO PRINCIPIO ACTIVO PLACEBO CONCENTRACION DEL PRINCIPIO ACTIVO 0MG INDICACIONES TERAPEUTICAS ESTUDIO DE FASE III ALEATORIZADO DOBLE CIEGO CONTROLADO CON PLACEBO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE
Expand
Trade date
2026/04/28
B/L No.
92003007532771
Suppliers
novartis pharma ag.
Buyers
novartis de col s.a.
POLs
——
PODs
bogota
Supply area
Switzerland
Purchas area
Colombia
Weight
22.45kg
Amount
17242.12
Hs code
3004321900
Product tags
medicament
Product description
DO 104100826 CODIGO OEA OE0091 PEDIDO PEDIDO EC-675 DECLARACION 1 DE 3PROTOCOLO: CQMF149G2301 // NOS ACOGEMOS AL DECRET
Expand
Trade date
2026/04/28
B/L No.
92003007532789
Suppliers
novartis pharma ag.
Buyers
novartis de col s.a.
POLs
——
PODs
bogota
Supply area
Switzerland
Purchas area
Colombia
Weight
0.26kg
Amount
199.61
Hs code
3006930000
Product tags
——
Product description
DO 104100826 CODIGO OEA OE0091 PEDIDO PEDIDO EC-675 DECLARACION 2 DE 3PROTOCOLO: CQMF149G2301 // NOS ACOGEMOS AL DECRET
Expand
Trade date
2026/04/28
B/L No.
92003007532796
Suppliers
novartis pharma ag.
Buyers
novartis de col s.a.
novartis pharma ag. is International Buyer&Supplier,
and primarily engages in the import and export business of products such as bat,e solid,equipped with fixed dose drug.
According to the 52wmb.com global trade database, as of 2026-05-30, the company has completed 66844 international trades,
with its main trading regions covering colombia,india,ecuador etc.
The core products include HS30049099,HS3004902900,HS98020000 etc,
often transported via basel,port basel switzerland mulhouse euroairport swiss, port viracopos etc,
and its main trading partners are novartis de colombia s.a.,novartis healthcare pvt ltd.,novartis ecuador s.a..
These trade data are sourced from various countries' customs and public channels, and have undergone standardization and structuring processing.
They can reflect the import and export trends and main market layout of the enterprise, and are suitable for market trend analysis, competitor research, port transportation planning, supply chain optimization, and international customer development.
They provide reliable support for cross-border trade decision-making.
The trade data displayed on novartis pharma ag. is sourced from the 52wmb.com global trade database. It is based on legal records from customs and related public channels of various countries, and has been formatted and organized for user query and analysis.
We maintain compliance with the source and processing of data to ensure the objectivity of information, but due to the dynamic changes in international trade activities, some data may be delayed or changed.